$16.08 Million in Sales Expected for MannKind Co. (NASDAQ:MNKD) This Quarter


Share on StockTwits

Brokerages forecast that MannKind Co. (NASDAQ:MNKD) will announce sales of $16.08 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for MannKind’s earnings. The highest sales estimate is $16.95 million and the lowest is $14.50 million. MannKind posted sales of $16.24 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, May 5th.

On average, analysts expect that MannKind will report full year sales of $75.46 million for the current year, with estimates ranging from $66.90 million to $80.98 million. For the next year, analysts forecast that the company will post sales of $86.91 million, with estimates ranging from $64.10 million to $118.44 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover MannKind.

MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The company had revenue of $18.44 million during the quarter, compared to analysts’ expectations of $16.13 million.

Several brokerages recently weighed in on MNKD. HC Wainwright raised their price objective on shares of MannKind from $2.50 to $6.50 in a research report on Friday, February 26th. Oppenheimer reaffirmed a “buy” rating and set a $7.00 price objective on shares of MannKind in a research report on Wednesday, February 17th. Zacks Investment Research raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Wednesday, March 3rd. SVB Leerink raised their price objective on shares of MannKind from $3.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday, March 11th. Finally, BTIG Research raised their price objective on shares of MannKind from $4.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, February 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. MannKind currently has an average rating of “Buy” and an average target price of $5.70.

MNKD traded down $0.01 during midday trading on Thursday, hitting $4.82. 2,972,891 shares of the company’s stock traded hands, compared to its average volume of 5,637,541. The company has a market cap of $1.20 billion, a PE ratio of -22.95 and a beta of 2.28. The stock’s fifty day simple moving average is $4.02 and its 200-day simple moving average is $3.54. MannKind has a one year low of $1.14 and a one year high of $6.25.

A number of institutional investors and hedge funds have recently bought and sold shares of MNKD. Aperio Group LLC acquired a new stake in MannKind during the fourth quarter worth $32,000. Pacer Advisors Inc. bought a new position in shares of MannKind in the fourth quarter valued at about $34,000. XTX Markets LLC bought a new position in MannKind in the fourth quarter valued at approximately $38,000. WealthTrust Axiom LLC bought a new position in MannKind in the first quarter valued at approximately $39,000. Finally, Versant Capital Management Inc bought a new position in MannKind in the first quarter valued at approximately $39,000. Hedge funds and other institutional investors own 29.60% of the company’s stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism.

Recommended Story: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on MannKind (MNKD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.